PSMA-targeted PET/CT was used for staging in newly diagnosed ccRCC patients in seven studies [29,30,33,34,36,37,42], to restage ccRCC patients with suspect relapsing disease in three articles [32,35,40], and for both purposes in the remaining four articles [31,38,39,41]. Here, FOLH1 is linked to nonpapillary renal cell carcinoma.